We would like to thank all of the participants and their families without whom the study would not have been possible. We are also grateful to the study teams who have worked tirelessly for years and to Laura White for her review of the manuscript.
Central TB Division, Directorate General of Health Services, Ministry of Health with Family Welfare, Nirman Bhavan, 2018. India TB Report 2018. Revised National Tuberculosis Control Programme Annual Status Report. New Delhi, India: Ministry of Health and Family Welfare.
Reid MJA 2019. The lancet commissions building a tuberculosis-free world: the lancet commission on tuberculosis. Lancet 393: 1331–1384.
Kolappan C, Subramani R, Karunakaran K, Narayanan P, 2006. Mortality of tuberculosis patients in Chennai, India. Bull World Health Organ 84: 555–560.
Verver S, Warren RM, Beyers N, Richardson M, van der Spuy GD, Borgdorff MW, Enarson DA, Behr MA, van Helden PD, 2005. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am J Respir Crit Care Med 171: 1430–1435.
Pablos-Mendez A, Knirsch CA, Barr RG, Lerner BH, Frieden TR, 1997. Nonadherence in tuberculosis treatment: predictors and consequences in New York city. Am J Med 102: 164–170.
Saqib SE, Ahmad MM, Amezcua-Prieto C, Virginia M-R, 2018. Treatment delay among pulmonary tuberculosis patients within the Pakistan national tuberculosis control program. Am J Trop Med Hyg 99: 143–149.
Jaggarajamma K, Sudha G, Chandrasekaran V, Nirupa C, Thomas A, Santha T, Muniyandi M, Narayanan P, 2007. Reasons for non-compliance among patients treated under revised national tuberculosis control programme (RNTCP), tiruvallur district, south India. Indian J Tuberc 54: 130–135.
Santha T 2002. Risk factors associated with default, failure and death among tuberculosis patients treated in a DOTS programme in Tiruvallur district, south India, 2000. Int J Tuberc Lung Dis 6: 780–788.
Babiarz KS, Suen S, Goldhaber-Fiebert JD, 2014. Tuberculosis treatment discontinuation and symptom persistence: an observational study of Bihar, India’s public care system covering >100,000,000 inhabitants. BMC Public Health 14: 418.
Jaiswal A, Singh V, Ogden J, Porter J, Sharma P, Sarin R, Arora V, Jain R, 2003. Adherence to tuberculosis treatment: lessons from the urban settings of Delhi, India. Trop Med Int Health 8: 625–633.
Roy N, Basu M, Das S, Mandal A, Dutt D, Dasgupta S, 2015. Risk factors associated with default among tuberculosis patients in Darjeeling district of West Bengal, India. J Fam Med Prim Care 4: 388–394.
Mehra D, Kaushik RM, Kaushik R, Rawat J, Kakkar R, 2013. Initial default among sputum-positive pulmonary TB patients at a referral hospital in Uttarakhand, India. Trans R Soc Trop Med Hyg 107: 558–565.
Hochberg NS 2017. Comorbidities in pulmonary tuberculosis cases in Puducherry and Tamil Nadu, India: opportunities for intervention. PLoS One 12: e0183195.
Leong S 2018. Existing blood transcriptional classifiers accurately discriminate active tuberculosis from latent infection in individuals from south India. Tuberculosis (Edinb) 109: 41–51.
Kubiak RW 2019. Interaction of nutritional status and diabetes on active and latent tuberculosis: a cross-sectional analysis. BMC Infect Dis 19: 1–9.
Hoyt KJ 2019. Effect of malnutrition on radiographic findings and mycobacterial burden in pulmonary tuberculosis. PLoS One 14: 1–11.
Central TB Division, Directorate General of Health Services, Ministry of Health with Family Welfare, Nirman Bhavan, 2017. National Strategic Plan for Tuberculosis Elimination 2017–2025. Revised National Tuberculosis Control Programme. New Delhi, India: Ministry of Health and Family Welfare.
Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA, 1998. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Arch Intern Med 158: 1789–1795.
Alkire S, Santos ME, 2014. Measuring acute poverty in the developing world: robustness and scope of the multidimensional poverty index. World Dev 59: 251–274.
Van Ness SE 2017. Predictors of delayed care seeking for tuberculosis in southern India: an observational study. BMC Infect Dis 17: 567.
Vasudevan K, Jayakumar N, Gnanasekaran D, 2014. Smear conversion, treatment outcomes and the time of default in registered tuberculosis patients on RNTCP DOTS in Puducherry, south India. J Clin Diagn Res 8: JC05–JC08.
Chang KC, Leung CC, Tam CM, 2004. Risk factors for defaulting from anti-tuberculosis treatment under directly observed treatment in Hong Kong. Int J Tuberc Lung Dis 8: 1492–1498.
Vijay S, Kumar P, Chauhan LS, Vollepore BH, Kizhakkethil UP, Rao SG, 2010. Risk factors associated with default among new smear positive TB patients treated under DOTS in India. PLoS One 5: e10043.
Yathiraj AB, Unnikrishnan B, Ramapuram JT, Kumar N, Mithra P, Kulkarni V, Holla R, Darshan B, Thapar R, 2016. Factors influencing adherence to antiretroviral therapy among people living with HIV in coastal south India. J Int Assoc Provid AIDS Care 15: 529–533.
International Institute for Population Sciences (IIPS) and ICF, 2017. National Family Health Survey (NFHS-4), 2015–2016. Mumbai, India: Ministry of Health and Family Welfare.
Lönnroth K, Roglic G, Harries A, 2014. Improving tuberculosis prevention and care through addressing the global diabetes epidemic: from evidence to policy and practice. Lancet Diabetes Endocrinol 2: 730–739.
Pizzol D, Di Gennaro F, Chhaganlal KD, Fabrizio C, Monno L, Putoto G, Saracino A, 2016. Tuberculosis and diabetes: current state and future perspectives. Trop Med Int Health 21: 694–702.
Kumarasamy N, Safren SA, Raminani SR, Pickard R, James R, Krishnan AK, Solomon S, Mayer KH, 2005. Barriers and facilitators to antiretroviral medication adherence among patients with HIV in Chennai, India: a qualitative study. AIDS Patient Care STDS 19: 526–537.
Yan S, Zhang S, Tong Y, Yin X, Lu Z, Gong Y, 2018. Nonadherence to antituberculosis medications: the impact of stigma and depressive symptoms. Am J Trop Med Hyg 98: 262–265.
Daftary A, Mitchell EMH, Reid MJA, Fekadu E, Goosby E, 2018. To end TB, first-ever high-level meeting on tuberculosis must address stigma. Am J Trop Med Hyg 99: 1114–1116.
Singla R, Khan N, Al-Sharif N, Al-Sayegh MO, Shaikh MA, Osman MM, 2006. Influence of diabetes on manifestations and treatment outcome of pulmonary TB patients. Int J Tuberc Lung Dis 10: 74–79.
Viswanathan V, Vigneswari A, Selvan K, Satyavani K, Rajeswari R, Kapur A, 2014. Effect of diabetes on treatment outcome of smear-positive pulmonary tuberculosis–a report from south India. J Diabetes Complications 28: 162–165.
Mi F 2013. Diabetes mellitus and tuberculosis: pattern of tuberculosis, two-month smear conversion and treatment outcomes in Guangzhou, China. Trop Med Int Health 18: 1379–1385.
Requena-Méndez A, Davies G, Ardrey A, Jave O, López-Romero SL, Ward SA, Moore DAJ, 2012. Pharmacokinetics of rifampin in Peruvian tuberculosis patients with and without comorbid diabetes or HIV. Antimicrob Agents Chemother 56: 2357–2363.
Nijland HMJ, Ruslami R, Stalenhoef JE, Nelwan EJ, Alisjahbana B, Nelwan RHH, van der Ven AJAM, Danusantoso H, Aarnoutse RE, Crevel RVan, 2006. Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clin Infect Dis 43: 848–854.
Baker MA, Lin H, Chang H, Murray MB, 2012. The risk of tuberculosis disease among persons with diabetes mellitus: a prospective cohort study. Clin Infect Dis 54: 818–825.
Kornfeld H, West K, Kane K, Kumpatla S, Zacharias RR, Martinez-Balzano C, Li W, Viswanathan V, 2016. High prevalence and heterogeneity of diabetes in patients with TB in south India. Chest 149: 1501–1508.
World Bank Group, 2019. Climate Data: India. Available at: https://climateknowledgeportal.worldbank.org/country/india/climate-data-historical. Accessed May 7, 2019.